Podcasts about Bayer

Weber State junior Braylyn Bayer takes medalist honors at the Utah Women's State Am at Oakridge by one over Sunbin Seo and Nya Palmer. The 32 player match play bracket is set with matches begining early on Tuesday morning. Bayer joins the pod. Sponsored by Goldenwest Credit Union. 

Endlich wieder Bayer 04 auf dem grünen Rasen! Die erste Trainingswoche liegt hinter uns und auch das erste Testspiel der Saison 2026/27 wurde mit 7:0 sehr deutlich gewonnen. Wo wurde gespielt? Ironischerweise in Monheim am Rhein, dort, wo man den Bayer-04-Campus wohl nicht bauen wird. Lara, Pippo und Kevin melden sich zurück nach einer guten sportlichen Woche, aber einer schwierigen politischen. Pippo hat am Rande des Testspiels gegen die Sportfreunde Baumberg mit Sportgeschäftsführer Simon Rolfes gesprochen und ein paar Zitate von Simon selbst gibt es in der heutigen Ausgabe, die sich um mehrere Themen dreht: Trainingsauftakt und eine neue Chance für alle ... Dieser Podcast wird vermarktet von der Podcastbude.www.podcastbu.de - Full-Service-Podcast-Agentur - Konzeption, Produktion, Vermarktung, Distribution und Hosting.Du möchtest deinen Podcast auch kostenlos hosten und damit Geld verdienen?Dann schaue auf www.kostenlos-hosten.de und informiere dich.Dort erhältst du alle Informationen zu unseren kostenlosen Podcast-Hosting-Angeboten. kostenlos-hosten.de ist ein Produkt der Podcastbude.

The Nurses Report with Nicole, Ashley & David – The Supreme Court's glyphosate ruling raises urgent questions about federal preemption, corporate liability, public health, and state authority. The Nurses' Report connects Bayer's Roundup case to broader concerns over regulatory capture, scientific uncertainty, warning labels, and local efforts to protect communities from preventable harm today...

The Nurses Report with Nicole, Ashley & David – The Supreme Court's glyphosate ruling raises urgent questions about federal preemption, corporate liability, public health, and state authority. The Nurses' Report connects Bayer's Roundup case to broader concerns over regulatory capture, scientific uncertainty, warning labels, and local efforts to protect communities from preventable harm today...

In this episode of Talk Dirt To Me, we're answering your farming questions and breaking down the biggest stories impacting agriculture right now. We kick things off with some listener Q&As before diving into Bayer's new hybrid wheat. Is it GMO? How much more yield are they claiming? Is the ROI better than saved seed, and could hybrid wheat change the future of grain production? From there, we take a deep dive into the latest USDA Crop Progress Report, highlighting why Tennessee continues to be one of the nation's most overlooked row crop states despite ranking among the top performers for crop conditions. We compare the top five states for corn rated good to excellent, discuss how much of the U.S. corn crop has reached the silking stage compared to last year, and what these numbers could mean for yield potential heading into harvest. We also examine the latest farm equipment sales numbers, which segment is surprisingly showing growth, and what declining equipment sales say about the current farm economy. Another major topic is the newly announced $11 billion in federal farm aid plus maximum ARC/PLC payments. Will the payments provide meaningful relief, or will they simply lead to higher seed, fertilizer, and chemical prices next season? International trade is back in the spotlight as we discuss the new tariffs on thousands of Brazilian products and the complicated relationship between Brazil, China, and American agriculture. Could these tariffs create new opportunities for U.S. farmers, or will they ultimately strengthen Brazil's position with China? And because no episode is complete without a little fun, we wrap up by talking about the recent Cyclospora outbreak, why leafy greens seem to make the news more often than steaks, and share guidance that eating more beef might be the safest strategy after all. If you enjoy honest conversations about farming, markets, policy, equipment, and everything happening in rural America, this is an episode you won't want to miss.  Go check out Agzaga! It is the ultimate online farm store. American owned and operated. Go check out their site and get what you need. Be sure to use the code TalkDirt20 to get $20 off your order of $50 or more! Visit them at: https://agzaga.com 

Welcome to this Friday edition of RealAg Radio with your host Shaun Haney! On today’s show, Haney is joined by Tyler McCann of CAPI, Lyndsey Smith and Kelvin Heppner of RealAgriculture for the RealAg Issues Panel. Also on today’s show, Curtis de Gooijer of Bourgault Ag joins Shaun for a product spotlight, and Anne Wasko... Read More

Welcome to this Friday edition of RealAg Radio with your host Shaun Haney! On today’s show, Haney is joined by Tyler McCann of CAPI, Lyndsey Smith and Kelvin Heppner of RealAgriculture for the RealAg Issues Panel. Also on today’s show, Curtis de Gooijer of Bourgault Ag joins Shaun for a product spotlight, and Anne Wasko... Read More

On this episode of the Precision Farming Dealer podcast, brought to you by the 2026 Dealership Minds Summit, we get the inside scoop on Leaps by Bayer's big investment in autonomous technology company Sabanto.

Send us Fan MailLifestyle and patient choices in Prostate CancerProstate cancer has been part of a revolution in terms of treatment options and improved outcomes for our patients. How can we make that improvement in numbers on survival curves match the goals and needs of our patients?Join us in this first of 2 special live episodes of the Simply Oncology Podcast on Patient Choices and Lifestyle in Prostate Cancer.We talk to patient expert Tony Collier, Dr Lucy Gossage - an oncologist involved with Move Against Cancer and  Professor Alison Birtle an oncologist with extensive experience treating prostate cancer.In this Episode  we talk to Tony Collier about his experience of being a prostate cancer patient. We hear how the focus on treatment led him to have to advocate his quality of life and life goals himself. We hear how clinicians could align with patients' goals with just a few simple questions. We hear about the huge positive impact that maintaining exercise has had on Tony's life with cancer. Hearing Tony's live experience of some very personal aspects of a cancer diagnosis and treatment is hugely moving and powerful.We hope you enjoy!*This is a non-promotional podcast episode organised by Bayer PLC in partnership with Simply Oncology (Dr John McGrane and Dr Michael Rowe) to highlight the importance of holistic care in managing patients with prostate cancer. Bayer provided honoraria to the speakers of this podcast. The views and opinions expressed are those of the speakers and do not necessarily reflect those of Bayer PLC or Simply Oncology. This content is for educational purposes only and should not replace clinical judgement.*

The gap between what you want and where you are isn't bad luck. It's a belief you made as a kid. David Bayer, author of A Changed Mind, calls it the Golden Equation: desire plus non-resistance equals your result. The block isn't the wanting. It's the meaning you attach to not having it yet. Somewhere between 40 and 60, the exact strategy that made you successful starts to suffocate you. Bayer calls it the Core Program, the compensation you built around a childhood wound that's finally asking to be healed. He spent years numbing himself with drugs, alcohol, sex and pornography before hitting bottom at 33. What got him sober wasn't willpower. It was learning to stop fighting his own thoughts. You don't need more hustle. You need less resistance. This conversation shows you exactly where yours is hiding. David's Website David on Instagram David on YouTube Take The Limiting Belief Assessment! A Changed Mind: Go Beyond Self Awareness, Rewire Your Brain & Reengineer Your Reality Amazon Audiobook In this episode you will: Learn the Golden Equation for turning desire into consistent results without hustle Discover why your Core Program hijacks your success between ages 40 and 60  Overcome limiting beliefs using David Bayer's Decision Matrix from A Changed Mind  Recognize the difference between primal states and powerful states in your nervous system  Build a personal relationship with a higher power through David's communion journaling practice For more information go to https://lewishowes.com/1954 More SOG episodes we think you'll love: Lewis Howes Solo [Ignore your limiting beliefs] Price Pritchett Katie Clarke Get More From Lewis! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Table of Contents: Did God send him an angel to help get the right diagnosis? Mold can be devastating to the human body—Guidelines for what to do about it Guidelines for using the Invive Mild Silver Protein for sinus infections–For lung infections–For Otitis Media (ear infections)–For an eye infection like Pink Eye++Mild Silver Protein Website: dr-johnson.com Listener Comment and Praise Report Regarding Lyme Disease / Dogs Treatment and Invive Silver What About an Invive Mild Silver Protein dosing chart for animals? Invive Silver Dosing Chart for children/babies & animals Pets Vaccines MRNA–Sadly most people will comply and will agree to allow their pets to get endless vaccines–But when we all say no, we gain that power back!! Listener Comment Cautioning Others About Veterinarians: This topic remains fresh for me and stirs up extreme righteous indignation. I agree with the video…if possible, avoid the vet like the plague. Last year I took my healthy cat into the vet with an infected toe pad. Her nail had grown abnormally and had curled into her pad. Very minor issue. They had to sedate her to trim the nail. Whatever they actually injected her with resulted in Triaditis (inflammation of 3 organs) and turbo cancer resulting in her rapid death. God only knows what they are actually giving our pets, both then and now… I investigated the explosion of ticks and what I found is horrifying… Outside Scavenger Animals Not Even Eating Organic Vegetables From Certain Grocery Stores Now! Supreme Court in a 7-2 decision prevents Roundup cancer suits against Bayer's Monsanto! Supreme Court Gives Monsanto TOTAL IMMUNITY – Glyphosate Now LEGALLY POISONING YOUR FOOD!! PDF: Emergency Freedom Alerts 7-13-26 Click Here To Play The Part 2 Audio Source

Welcome to RealAg Radio with your host, Shaun Haney! On today's show, Haney is joined by Dr. Edward Bork of the University of Alberta to discuss virtual fencing on Western Canadian ranches, Tim Gardner of Bayer for a spotlight interview, and Blaine Woycheshin of BASF to look back on 30 years of InVigor canola. Coming... Read More

This week on The Agronomists, guest host Peter Johnson is joined by Adrian Rivard of Drone Spray Canada and Adam Pfeffer of Bayer to discuss spraying by drone — what the new rules say, the impact of spray height, water volume, and speed on efficacy. The Agronomists is brought to you by the Edible Bean... Read More

Welcome to RealAg Radio with your host, Shaun Haney! On today's show, Haney is joined by Dr. Edward Bork of the University of Alberta to discuss virtual fencing on Western Canadian ranches, Tim Gardner of Bayer for a spotlight interview, and Blaine Woycheshin of BASF to look back on 30 years of InVigor canola. Coming... Read More

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest news and insights that are shaping the landscape of patient care and drug development. The U.S. FDA has expanded the label for Pfizer and Astellas' Padcev, in combination with Merck's Keytruda, to include all muscle-invasive bladder cancer patients. This significant regulatory update broadens access to a combination therapy that merges an antibody-drug conjugate with a PD-1 inhibitor, offering enhanced treatment options for patients unable to tolerate cisplatin, a common chemotherapy drug. The decision marks a pivotal step forward in providing more inclusive and effective treatment regimens for bladder cancer. In Scotland, Roche's Columvi has been endorsed by the Scottish Medicines Consortium for use in treating relapsed or refractory diffuse large B-cell lymphoma. This approval highlights the growing importance of bispecific antibodies in oncology, which can simultaneously engage two different antigens to enhance anti-tumor responses. Such innovations underscore the ongoing transformation of cancer treatment through combination therapies. Across the Atlantic, Health Canada has approved Clinuvel's Scenesse for erythropoietic protoporphyria (EPP), a rare condition causing extreme light sensitivity. Scenesse acts as a melanocortin receptor agonist, offering photoprotection and improving quality of life for those affected by this debilitating disorder. On the business front, Bayer's strategic partnership with Apollo has secured a €3 billion equity deal for its long-acting reversible contraceptives business. This move underscores a growing emphasis on women's health and contraceptive innovation. Likewise, CMS and Insilico's collaboration aims to harness artificial intelligence for CNS drug discovery, promising to accelerate drug development through AI-driven target identification. Clinical trials continue to reveal promising developments. Eisai's Etalanetug is showing potential in reducing tau tangle biomarkers in dominantly inherited Alzheimer's disease. Similarly, Eisai and BioArctic's Leqembi subcutaneous autoinjector demonstrates comparable efficacy to its intravenous counterpart, potentially improving compliance and accessibility for early Alzheimer's patients through less invasive administration methods. Financially, Apnimed is planning an IPO to support its sleep apnea pill's commercial launch, while Velogene Biotechnology has secured Series A funding to advance its gene-editing platform. These financial activities highlight ongoing investments in innovative solutions aimed at addressing unmet clinical needs. Yet, challenges persist as well. The FDA has rejected Hengrui and Elevar Therapeutics' combination treatment for hepatocellular carcinoma for a third time, emphasizing the difficulties of meeting regulatory standards and demonstrating efficacy. Additionally, Germany's new healthcare cost-saving law has doubled pharmaceutical rebate rates, sparking industry concern over potential impacts on profitability and innovation investment. The regulatory landscape continues to evolve with the FDA proposing streamlined registration processes under the "hub-and-spoke" model to enhance transparency and security within supply chains. Meanwhile, recent FDA transparency actions have led to the release of 14 drug rejection letters, underscoring ongoing challenges in securing approvals due to stringent regulatory requirements. Geographically, emerging biotech hubs like Basel and Beijing are gaining prominence as global talent hotspots due to their conducive environments for research and development collaboration. These regions are becoming increasingly attractive for biopharmaceutical innovation. Amid fierce competition in obesity management solutions, Lilly's launch of its oral GLP-1 receptor agonist Foundayo faces stiff competition from Novo Nordisk's Wegovy pill. The race reflects broader trends toward developing patient-centric therapies that offer convenience alongside therapeutic efficacy. Intellectual property strategies are also evolving as companies employ new patent tactics to maintain competitive advantages in crowded markets. Safety remains a top priority as exemplified by Lupin Pharmaceuticals' recall of contaminated eye drops, highlighting ongoing challenges in ensuring product safety. Lastly, advancements in wearable technology offer promising improvements in patient care; however, integration into clinical practice is met with infrastructural hurdles—a sentiment echoed by healthcare professionals surveyed by the AMA. Overall, these developments paint a complex picture of scientific innovation intersecting with regulatory evolution and strategic industry adaptations aimed at enhancing patient outcomes while navigating economic pressures. As the industry evolves, stakeholders must remain vigilant and adaptable to seize opportunities and address challenges effectively.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative updates and strategic shifts within the industry, reflecting both remarkable progress and inherent challenges. Sanofi's recent achievement marks a significant milestone in oncology with the FDA approval of Sarclisa Escena (isatuximab) as the first on-body injector for multiple myeloma treatment. This monoclonal antibody, targeting CD38, offers a novel subcutaneous delivery method, simplifying administration and potentially enhancing patient compliance by reducing the need for frequent clinic visits. This aligns with the industry's ongoing shift towards patient-friendly drug delivery systems, emphasizing convenience without compromising efficacy. In another promising development, GSK and Hansoh Pharmaceutical have reported positive results from their Phase 3 trial evaluating risvutatug rezetecan for small cell lung cancer. This antibody-drug conjugate, targeting B7-H3, has shown potential when combined with chemotherapy to extend patient survival. Given the aggressive nature of small cell lung cancer and limited treatment options, these findings underscore the potential of targeted therapies to improve clinical outcomes significantly. Forte Biosciences' FB102 also takes a spotlight in clinical advancements. In its Phase 1b trial for vitiligo, FB102 demonstrated a 45.8% placebo-adjusted benefit. This monoclonal antibody works by modulating immune responses through the IL-15 pathway via CD122, offering new hope for patients with this challenging autoimmune condition. On the regulatory front, ARPA-H's commitment of up to $160 million towards developing personalized genetic medicines for rare diseases is noteworthy. This investment is set to accelerate innovations in gene therapy and personalized medicine platforms. Such advancements promise to revolutionize pediatric care and extend beyond by tailoring treatments to individual genetic profiles, enhancing efficacy while minimizing adverse effects. Strategic collaborations continue to reshape the industry landscape. Rani Therapeutics' partnership with PegBio aims at advancing oral delivery systems for obesity and metabolic diseases. Similarly, Simcere Pharmaceutical's collaboration with Schrödinger leverages AI-driven drug discovery efforts. These alliances highlight an increased reliance on computational platforms to streamline therapeutic development processes. From a financial perspective, Mesoblast Limited reports substantial revenue from its cell therapy product Ryoncil, signaling strong commercial viability for cell-based treatments targeting rare diseases. Additionally, Cue Biopharma's successful $50 million fundraising underscores investor confidence in advancing therapies for immunological disorders. However, not all news is positive. Roche has decided to halt two programs targeting Huntington's disease due to inadequate efficacy and safety concerns. This decision reflects the complexities involved in developing effective treatments for neurological disorders—a field fraught with scientific challenges yet rich with potential rewards. In market dynamics, McKinsey's report advocates for a structural redesign of biopharmaceutical R&D to fully leverage AI's capabilities. This recommendation resonates with current industry trends focusing on strategic innovation to maximize efficiency and discovery potential. The FDA's third rejection of Hengrui Pharma and Elevar Therapeutics' combination therapy for liver cancer underscores the rigorous scrutiny such treatments face despite their promise in addressing complex cancers. In contrast, BioNTech's preparation to launch its HER2 antibody-drug conjugate (ADC) signifies its strategic pivot back towards oncology after mRNA vaccine successes. Bayer's decision to sell a minority stake in its contraceptives business demonstrates how companies are strategically realigning portfolios to focus on core areas while securing funding for innovation. This move reflects broader trends within pharma as companies navigate financial landscapes to support long-term research goals. Amid these developments, regulatory environments continue evolving. NICE's stance against future Lumakras reimbursement in the UK highlights ongoing challenges in balancing cost-effectiveness with access to innovative therapies. Meanwhile, ARPA-H's significant funding allocation signals robust governmental support for advancing precision medicine within genetic therapies. In conclusion, today's updates reveal an industry characterized by a relentless pursuit of innovation amidst complex regulatory landscapes. As companies navigate these dynamics through strategic collaborations and scientific breakthroughs, their efforts hold promise for enhancing patient care across diverse therapeutic areas globally. Stay tuned as we continue to track these exciting developments shaping the future of pharmaceuticals and biotechnology. Thank you for tuning into Pharma Daily—your go-to source for up-to-date insights from the world of pharmaceuticals and biotechnology.Support the show

Live July 10, 2026 | Yaron Brook Show(Season 12, Episode 120)Platner; Far Left; ICE; Cronyism; Rent Control; Freya; Climate; Kirk; Achievement | Yaron Brook ShowIs America Choosing Tribalism Over Reason? ICE, Rent Control, Climate Panic & the Collapse of PoliticsHas America abandoned reason for tribalism? Why do political scandals disappear, bad ideas keep winning, and conspiracy theories flourish while serious debate dies?In this episode of The Yaron Brook Show, Yaron examines the Graham Platner controversy, the Democratic Party's drift toward the far left, the continued collapse of America's political center, ICE enforcement, immigration rights, rent control, climate litigation, Ukraine's newest defense technology, Bayer's Supreme Court victory, and why conspiracy thinking has become mainstream across both the left and right.Along the way, Yaron explores what these stories reveal about today's political culture—and why philosophy ultimately matters more than politics.  Topics include:00:00 Introduction & Bonnie Tyler tribute03:00 Graham Platner scandal & Democratic Party response10:16 Stephen King, cancellation & resignation14:04 Tribalism, religion & political morality16:24 Abdul El Sayed's agenda examined27:15 Why isn't anyone challenging bad ideas?29:09 The future of Democrats & Republicans31:03 Trump and the collapse of the political center32:59 Michigan politics, UAW & electoral strategy34:57 ICE shooting in Houston37:28 Mistaken identity and legal responsibility39:14 Media bias and accountability44:00 Illegal immigration, rights & ICE authority47:11 Supreme Court ruling on Haitian refugees54:19 Bayer wins at the Supreme Court59:15 Glyphosate, tariffs & farmers1:02:15 Why rent control remains popular1:07:03 Ukraine's new anti-ballistic missile system1:12:54 International Court of Justice climate ruling1:17:43 Candace Owens & Charlie Cook conspiracy theories1:27:16 Americans are living longer1:33:08 Right-wing vs. left-wing political violence1:34:41 Documentary fundraising update1:36:31 Preview: Egalitarianism in Cambodia1:37:33 Dr. Mike Israel on capitalism1:40:42 Ayn Rand, individualism & philosophyLive Audience Questions1:40:39 Choosing life over religion—how should someone respond?1:42:26 Michael Jackson: genius or something else?1:43:50 Should Yaron cover Ayn Rand's "Man's Rights"?1:47:33 Is ICE's leadership the real problem?1:48:12 Should ICE agents face criminal charges?1:48:25 Why is Mamdani succeeding politically?1:49:18 Is Trump's administration fundamentally unserious?1:49:58 Is Kash Patel the weakest member of the administration?1:50:28 Japan, Europe & China's attitudes toward failure1:51:08 Would an Objectivist society eliminate "weirdness"?1:51:36 Gulags vs. concentration camps—which was worse?If you enjoy serious discussions of philosophy, economics, politics, investing, technology, and current events from an Objectivist perspective, subscribe and turn on notifications so you never miss a live show. Watch Now: https://youtube.com/live/ZVjbmjIhmsQ#Objectivism #Politics #Capitalism #ICE #RentControl #ClimateChange #Ukraine #SupremeCourt #CurrentEvents #Iran #ICE#TrumpThe Yaron Brook Show is Sponsored by[The Ayn Rand Institute](https://www.aynrand.org/starthere)[Energy Talking Points, featuring AlexAI, by Alex Epstein](https://alexepstein.substack.com/)[Express VPN](https://www.expressvpn.com/yaron)[Hendershott Wealth Management](https://www.youtube.com/watch?v=X4lfC...) &(https://hendershottwealth.com/ybs/)[Michael Williams & The Defenders of Capitalism Project](https://www.DefendersOfCapitalism.com)[Support the Show]( / yaronbrookshow )[Sponsor the Show](askyaron@yaronbrookshow.com/)[One-time donation](https://bit.ly/2RZOyJJ)Join the [Yaron Brook Show YouTube channel]( / @yaronbrook )Like what you hear? Like, share, and subscribe to stay updated on new videos and help promote the [Yaron Brook Show](https://bit.ly/3ztPxTx)Continue the discussion by following Yaron on [Twitter](https://bit.ly/3iMGl6z) and [Facebook](https://bit.ly/3vvWDDC )Want to learn more about Ayn Rand and Objectivism? Visit the [Ayn Rand Institute](https://bit.ly/35qoEC3)Become a supporter of this podcast: https://www.spreaker.com/podcast/yaron-brook-show--3276901/support.Yaron is the executive chairman of the Ayn Rand Institute and a world class speaker. He is the coauthor of the national best-seller Free Market Revolution: How Ayn Rand's Ideas Can End Big Government, Equal is Unfair: America's Misguided Fight Against Income Inequality and In Pursuit of Wealth: The Moral Case for Finance. He speaks around the world on a variety of topics including the morality of capitalism, Ayn Rand and her philosophy, finance and economics, and the value of inequality.

Wet weather can create ideal conditions for fungal diseases in cereal crops, making timely scouting and well-planned fungicide applications very important. While growers can't control the weather, they can improve disease management by focusing on prevention, staging, and field prioritization. In this episode of RealAgriculture's Wheat School, Rory Cranston, technical product lead with Bayer, joins... Read More

Support the pod on Patreon With so much emphasis on global politics and the World Cup in recent weeks, we're going to focus on the somewhat quieter but intensely important bureaucratic dismantling of expertise occurring in health and science. First, Derek looks into a recent 412-page OMB proposal that hands political appointees veto power over federal science grants, effectively killing peer review, blocking research on health disparities, and walling off American scientists from the rest of the world. Matthew counters with Canada's own corrosive behavior. Then we dig into the contradiction of MAHA: the pro-health movement running cover for the EPA quietly approving new forever chemical pesticides mere days after the Supreme Court gutted Americans' ability to sue Monsanto (by way of their parent company, Bayer). Again, there's a Canadian parallel: Bill C-30 hands cabinet the power to override Health Canada's own scientists and approve pesticides they've already ruled unsafe. Finally, Julian removes gravity from the situation by covering congressional UAP hearings where unverified whistleblower claims about alien bodies and secret programs get treated with peer-reviewed science seriousness. Only, as with everything else in Trump's America, the science is thin and the theater, thick. Show Notes The war against ‘woke' could end US science as we know it Carney's government is cutting hundreds of environment and science jobs Departmental plans fuel concern over federal job, program cuts Environment Canada disbands radar research team amid cuts to weather services Weather experts concerned about public safety as Environment Canada disbands radar research team Carney government passes law allowing authorization of banned pesticides Pesticide regulation changes raise questions in Northeastern Ontario Amendments buried in Bill C-30 weaken environmental protections Former Haiti prime minister Smarck Michel dies at 75 Omnibus I: the EU concludes CSDDD and CSRD reforms EU scales back corporate due diligence and reporting rules Australia: Labor-Greens deal to fast-track mining and military projects Task Force Tackles MK Ultra UFO Disclosure Movement Goes To Washington Learn more about your ad choices. Visit megaphone.fm/adchoices

Host: Emer Joyce Guests: Marianna Fontana Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/2551   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies AI & digital solutions in emergency medicine Management of heart failure in cardiac amyloidosis Spotlight: Orthodexia-Platypnoea Syndrome Host: Emer Joyce Guests: Marianna Fontana, Wolf Hautz, Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2551 Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Wolf Hautz and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.  Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Glyphosate is in the news again. The US Supreme Court has sided with Trump in protecting Monsanto (and Bayer) from legal immunity over Roundup-caused cancer. But what does it all mean? Let's find out with Dr. Michael Antonious, a world-renowned expert in glyphosate toxicology.

Glyphosate is in the news again. The US Supreme Court has sided with Trump in protecting Monsanto (and Bayer) from legal immunity over Roundup-caused cancer. But what does it all mean? Let's find out with Dr. Michael Antonious, a world-renowned expert in glyphosate toxicology.

Nick looks back at one of his favorite Saturday Night Live characters of all time, Jacob the Bar Mitzvah Boy. Created and performed by Vanessa Bayer, Jacob is an awkward 13-year-old Jewish kid and die-hard Yankees fan who delivers painfully corny, carefully rehearsed jokes from a binder on Weekend Update. Inspired by Bayer's real-life brother Jonah, the character quickly became a fan favorite. Nick revisits some of Jacob's funniest appearances, shares the story behind how the character was created, and digs into behind-the-scenes moments from Bayer's time on the show. The episode also features one of Jacob's best moments, a special appearance by Billy Crystal as his father. A hilarious look back at one of Weekend Update's most lovable oddballs. [Ep 183]

Join us as we welcome Aaron Bayer to talk about Tropical Milksnakes Zac Loughman https://www.instagram.com/dr_crawdad/On FB https://www.facebook.com/zac.loughmanClint Bartley @ IG: MetazoticsLLC Website: metazotics.com Patreon: https://patreon.com/ColubridandColubroidRadioDiscord: dicord.gg/ccradioExo-terra https://exo-terra.com https://linktr.ee/exoterrausa MPR Network FB: https://www.facebook.com/MoreliaPythonRadioIG: https://www.instagram.com/morelia_python_radio/YouTube: https://www.youtube.com/@mprnetwork5623Swag store: https://teespring.com/stores/mprnetwork ★ Support this podcast on Patreon ★

Send us Fan MailThere are very few cures for cancers that have already spread. So what does a good outcome actually look like?In this clip from our episode “How Targeted Radiotherapy Is Changing Cancer Care”, host David E. Williams and John Babich, Founder, President, and Chief Scientific Officer of Ratio Therapeutics, break down what extending life with quality really means in cancer care, and why giving someone eight more months where they can still live their life is the philosophy driving the work at Ratio Therapeutics.Listen to the full episode here

This Day in Legal History: Vermont Bans SlaveryOn July 8, 1777, delegates meeting in Windsor adopted the Constitution of the Vermont Republic—and in doing so, Vermont became the first place in North America to write the prohibition of slavery into its founding law. At a moment when the newly declared United States tolerated and protected human bondage, a small, unrecognized republic on the frontier put a very different principle on paper.The relevant language was striking for its era. The Vermont constitution declared that all people are born equally free and independent, and it provided that no adult could be held as a servant, slave, or apprentice against their will—specifically, no man over twenty-one and no woman over eighteen. It was not a complete abolition; the age limits meant the document did not immediately free everyone, and enforcement in practice was uneven and incomplete for years afterward. But as a matter of constitutional text, it was the first time on this continent that a government's foundational law declared slavery inconsistent with the very idea of being born free.The context matters. In 1777, Vermont was not yet a state—it wouldn't join the Union until 1791—and it existed in a kind of legal limbo, claimed by both New York and New Hampshire and recognized by neither. That outsider status may have given its drafters room to be bolder than their contemporaries. While the framers of the national government were negotiating the compromises that would embed slavery in American law for another four generations—the three-fifths clause, the fugitive slave clause, the twenty-year protection of the slave trade—Vermont's drafters wrote the opposite conviction into their first article.The significance of July 8, 1777 is partly symbolic and partly practical. Symbolically, it established that abolition was not some later invention imposed on a reluctant founding generation, but a principle that existed at the founding itself, chosen by people who could see the contradiction between declaring all men free and holding some in bondage. Practically, Vermont's provision became an early data point in the long argument that would run through the Northwest Ordinance, the gradual emancipation statutes of the northern states, the abolitionist movement, the Civil War, and finally the Thirteenth Amendment. It's a reminder that constitutional law is not just handed down from the most powerful actors—that sometimes the boldest legal principles come from the margins, from a place that wasn't even sure it counted as a state, writing down what it believed the law ought to be.A former Milwaukee County judge, Hannah Dugan, has been sentenced in federal court after being convicted of obstructing an immigration arrest outside her courtroom—a case that became a flashpoint in the fight over the Trump administration's use of courthouses to stage immigration enforcement. Dugan, who is 67 and was an elected circuit court judge, was found guilty of obstructing a federal proceeding, though a jury acquitted her of a lesser concealment charge.Federal immigration agents came to Dugan's courthouse to arrest Eduardo Flores-Ruiz, a Mexican man who was scheduled to appear before her on misdemeanor assault charges. Prosecutors said Dugan directed him out through a non-public “jury door” in an effort to help him avoid the agents waiting in the public hallway. It didn't work—Flores-Ruiz walked through a public hallway with his attorney anyway, and agents arrested him outside after a brief foot chase. But the government charged Dugan criminally for what she did inside the courthouse, and a federal jury convicted her in December.Think about the competing principles colliding here. On one side is the idea that no one, not even a judge, gets to physically obstruct federal law enforcement carrying out its duties. On the other is a real institutional worry that animated a lot of the coverage: if immigration agents stake out courthouses, people with pending cases—victims, witnesses, defendants—may stop showing up at all, which grinds the ordinary work of the state courts to a halt. Dugan's defenders framed her actions as protecting the functioning of her courtroom; prosecutors framed them as obstruction of a federal operation. The jury sided with the government on the core charge.At sentencing, the two sides were far apart. Federal prosecutors declined to recommend a specific term but argued the guidelines called for fifteen to twenty-one months in prison. Dugan's lawyers disputed that calculation and asked U.S. District Judge Lynn Adelman for time served—no prison at all. The significance of the case goes well beyond one judge. It's a marker of how aggressively the administration is willing to pursue anyone perceived to interfere with immigration enforcement, up to and including a sitting judge, and it sends a message to state and local officials everywhere about the personal legal risk of getting between federal agents and their targets.Ex-Wisconsin judge to be sentenced for obstructing immigration arrest | ReutersBayer is moving to bring an end to the sprawling federal litigation over its Roundup weedkiller, following a significant win at the Supreme Court. Late last month, the Court ruled 7-2 in Bayer's favor, and the company is now trying to convert that decision into the dismissal of the failure-to-warn claims that have driven nearly a decade of lawsuits.Thousands of plaintiffs have sued Bayer alleging that Roundup, and specifically its active ingredient glyphosate, caused their non-Hodgkin lymphoma, and that the company violated state law by failing to warn them of that cancer risk. Bayer's winning argument was about federal preemption—the principle that when federal and state law conflict, federal law wins. Bayer argued that because the Environmental Protection Agency has concluded glyphosate poses no cancer risk and requires no cancer warning on the label, plaintiffs can't use state failure-to-warn law to demand a warning the federal regulator affirmatively says isn't needed. The Supreme Court agreed, overturning a $1.25 million Missouri verdict in the process.Consider why this is such a powerful tool for Bayer. A failure-to-warn claim says, in essence, “you should have told me this was dangerous.” But if the federal agency in charge has studied the product and decided no warning is warranted, then a state jury ordering the company to warn anyway would effectively be overriding the federal regulator. Preemption resolves that conflict in favor of the federal standard. The practical effect is that the single most common theory in the Roundup litigation—failure to warn—is now largely off the table in the cases this ruling reaches.The significance is real but, importantly, not total. This should let Bayer dismiss current warning-based claims and block future ones, which is exactly why the company is now pressing courts to wind down the federal litigation, and it's pairing that push with a proposed $7.25 billion class-action settlement to sweep in remaining Roundup users. But the decision doesn't make every claim disappear. Plaintiffs may still pursue theories that don't depend on a failure to warn—like defective design—and the settlement obligations remain. So this is a milestone in Bayer's long campaign to contain its liability, not the final word. It's also a notable example of how federal regulatory findings can become a shield against state tort law, a doctrine with implications well beyond weedkiller.Bayer seeks end to federal Roundup litigation after Supreme Court win | ReutersFederal judges are sounding skeptical of a California law that bans employers from forcing workers to attend so-called “captive audience” meetings—mandatory gatherings where a company shares its views on political or religious matters, most often its opposition to unionizing. The law has already been blocked by a district court, and the signs from the bench suggest that skepticism may carry through on appeal.Here's what a captive audience meeting is and why it's contested. When a union organizing drive is underway, employers have long held mandatory meetings where attendance is required and workers listen to management make the case against unionizing. Unions call these coercive; employers call them protected speech. California's SB 399 tried to ban compelling attendance at meetings covering “political matters,” a category defined broadly enough to include unionization. Judge Daniel Calabretta of the Eastern District of California blocked the law, and his reasoning is the crux of the whole fight.He gave two independent grounds, and it's worth separating them. The first is federal preemption—the same principle at work in the Bayer story. Calabretta found that the National Labor Relations Act, which governs labor relations nationwide, occupies this field and preempts California's attempt to regulate it under the Machinists and Garmon preemption doctrines. The second ground is the First Amendment: he held that the law was a content-based restriction on employer speech, singling out “political” and “religious” topics, and that it couldn't survive strict scrutiny—the most demanding test in constitutional law, which almost nothing passes. In his view, banning all speech on those topics in mandatory meetings swept far too broadly.The significance here is that this is a collision between the labor movement's priorities and employers' free-speech claims, and right now the free-speech and preemption arguments are winning in court. A number of states have passed captive-audience bans, so how the Ninth Circuit ultimately rules—California and Attorney General Rob Bonta are expected to appeal—will shape whether this entire category of worker-protection law survives. It's a reminder that even popular labor legislation has to run a gauntlet of federal preemption and the First Amendment, and that employer speech, including anti-union speech, gets substantial constitutional protection.US judges leery of California ban on workplace captive-audience meetings | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Xavier Brun, responsable de renta variable de Trea AM, pone el foco sobre Airbus, Unicredit y Bayer, entre otros.

A growing reliance on data‑driven systems is creating tension for enterprise leaders between operational efficiency and the human judgment required for high‑risk, high‑reward decisions. In this episode, Kun He, Lead Scientific Advisor at Bayer, examines how AI improves agricultural decision‑making while still leaving critical gaps that only human intuition and risk tolerance can fill, in conversation with host Matthew DeMello. He highlights where AI reliably accelerates complex workflows and where leaders must preserve the capacity to recognize outlier opportunities and make unconventional calls that data alone would never surface. Learn how to structure landing pages for higher conversion and how to use self-qualification systems to prioritize high-intent leads. Download our free PDF report, "B2B AI Lead Generation Guide," at emerj.com/aig1

There is a fundamental link between diabetes and kidney care. But while there are many medications available to improve CKD outcomes in people with type 2 diabetes, the same options are not available for people with type 1. In this special episode, Dr. Neil Skolnik speaks with Janet McGill, MD, MA, FACE, FACP about the underdiscussed prevalence of CKD in type 1 and the importance of continued development in this area. This special episode is sponsored with support from Bayer. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Janet B. McGill, MD, MA, FACE, FACP, Professor of Medicine at the University of Washington's John T. Milliken Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research Selected References: Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1):S246–S260 Finerenone in Type 1 Diabetes and Chronic Kidney Disease. N Engl J Med 2026;394:947-957 Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229 Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446 Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121

This Monday edition of the Closing Market Report highlights a major, post-holiday surge across the agricultural commodity markets, driven primarily by an adverse late-summer weather forecast and renewed export interest from China. Host Todd Gleason reports substantial gains in corn, soybean, and wheat futures following recent contract lows. Market analyst Curt Kimmel of AgMarket.net discusses the logistical significance of China picking up soybean cargoes off the Pacific Northwest and the Gulf, noting that while the technical fundamentals haven't shifted, the buying enthusiasm provides critical support ahead of Friday's upcoming USDA WASDE report. In agricultural news, farm groups are actively pushing back against Bayer's request for anti-dumping duties on Chinese glyphosate imports due to concerns over narrowing farmer margins. Additionally, University of Illinois Extension entomologist Nick Seiter warns producers to actively scout for corn leaf aphids as crops enter their vulnerable tasseling stage, and Senate Agriculture Chair John Boozman expresses hope to transition foreign food aid programs back under the jurisdiction of the USDA via a new farm bill.The program also features an in-depth economic perspective from University of Minnesota Extension economist Ed Usset, who views the current market rally as a classic post-July 4th weather market. While acknowledging the bump from hot, dry domestic forecasts and extreme heat hitting crops in France, Usset reminds producers that this rally serves as an excellent "second chance" to clean out remaining old crop inventories and execute scale-up sales on new crop corn and soybeans before defensive seasonal trends potentially return. Finally, Mark Russo of EverStream Analytics breaks down the broader global weather patterns, noting that while the core U.S. Midwest looks secure, a highly intense ridge of high pressure will bring crop-stressing heat to western plains states like Nebraska, Kansas, and South Dakota next week. Internationally, Russo reports a disastrous third heat wave accelerating crop deterioration for  corn in France and parts of Eastern Europe, while unseasonal winter rains slightly slow the safrinha corn harvest in southern Brazil.01:35 Ag Markets with Curt Kimmel, AgMarket.net07:20 Bayer Requests Glyphosate Import Protections08:00 Scout for Corn Aphids09:12 Farm Bill Legislation May Attempt to Move Foreign Food Aid10:54 Commodity Market Discussion with Ed Usset, University of Minnesota18:04 Ag Weather with Mark Russo, EverStream Analytics ★ Support this podcast ★

Sermon delivered on the Sixth Sunday After Pentecost, 2026, at Queen of All Saints chapel in Pottstown, Pennsylvania, by Rev. Tobias Bayer.  Epistle: Rom. 6, 3-11 | Gospel: Mark 8, 1-9

Last week the Supreme Court ruled seven to two in favor of Bayer-Monsanto, and it changes the rules for anyone who gardens, farms, or eats food grown in this country. Notice they did not go to the highest court in the land to prove Roundup is safe. They went to argue that even if it causes cancer, you are no longer allowed to sue them in your own state for failing to warn you. In this episode I walk you all the way through it. Not the headline, the whole thing. What the ruling actually says and why the legal logic is so slippery. The real story of who Bayer even is and why a drug company bought a pesticide company. The billions already paid out in cancer settlements, and the trap door that just closed. And then, because despair is just laziness in a nicer outfit, exactly what you and I do about it, starting today, with our hands and our habits and our dollars. You have more power here than you have been told. Let's use it. What We Cover Who John Durnell is, and the twenty-plus years of Roundup use behind this case What the ruling actually says, in plain English: FIFRA, the EPA, and the "Uniformity" clause that decided everything Why the legal reasoning is so slippery, and what the bipartisan dissent from Justices Jackson and Gorsuch warned about The honest version of the science fight: what the World Health Organization said versus what the EPA says Three branches of government, one year, moving in the same direction, and the one piece the people actually stopped Why a pharmaceutical company bought a pesticide company, and the structure underneath "create the problem, sell the cure" The settlement numbers, and the question they cannot answer: why pay billions for a product you swear is safe? What this precedent means for every other industry going forward What practical steps you can take right away The Receipts A few of the numbers and facts from this episode, so you have them: The case is Monsanto Co. v. Durnell, decided seven to two on June 25, 2026. Justice Kavanaugh wrote the majority. Justice Ketanji Brown Jackson dissented, joined by Justice Neil Gorsuch. The ruling reversed a Missouri jury's verdict that had awarded John Durnell one point two five million dollars on a failure-to-warn claim. In 2015, the World Health Organization's cancer research arm classified glyphosate as probably carcinogenic to humans. The EPA has concluded it is not likely to cause cancer when used as directed, and never required a warning label. In 2020, Bayer agreed to pay nearly eleven billion dollars to settle around a hundred thousand cancer claims. The company has spent well over ten billion total, and proposed another settlement of seven and a quarter billion in February 2026. In February, the President signed an executive order invoking the Defense Production Act to boost glyphosate production, though experts question whether it even reaches these lawsuits. A push to shield pesticide companies from these lawsuits in the Farm Bill was stripped out in late April by a bipartisan vote of two hundred eighty to one hundred forty two. The people stopped that one. What You Can Do Lower your toxic load where you can. Start with personal care products, the things you put on your skin every day. Skip drinking from, storing food in, and especially microwaving plastic when you have a glass or steel option. Know where your food comes from. Rinse and soak your produce before you eat it. This is the produce wash/soak product I use.  Grow some of your own, even a little. One tomato plant on a balcony is more food sovereignty than most Americans have. Start absurdly small. Just start. Support local farms, and then ask the question. Find a farm you trust, and kindly ask them about their spraying practices. Give your money on purpose to the people who opt out. Support your body's own systems. Sweat regularly, move consistently, and give your gut real breaks between meals. Move, sweat, rest, repeat. None of this is medical advice or a substitute for your doctor, it is everyday support for a body built to handle a tough world. Resources and Links The produce wash and soak method I use:  https://amzn.to/4xWl2DI Want to read the ruling yourself? Look up Monsanto Co. v. Durnell, decided June 25, 2026. Find a local farm or market near you and start the conversation about how your food is grown.  

Jordan Sather and Nate Prince are back from GART and not wasting any time. A parasite called cyclosporiasis is ripping through Michigan and beyond, and Jordan reads the New York Post's most colorful victim profile of the year. A Michigan couple faces second degree murder charges after their 7-year-old son died at 255 pounds, prompting a raw conversation about parenting, dopamine addiction, and personal accountability. The DOJ just charged 455 defendants in 45 states on National Healthcare Fraud Takedown Day, with $6.5 billion in stolen funds at stake. Kennedy terminates the COVID-19 Emergency Use Authorization, stripping legal protections from the shots and dropping what may be a signal that Fauci accountability is building. Then the Supreme Court throws cold water on the MAHA movement with a 7-2 ruling protecting Bayer from glyphosate lawsuits. Jordan and Nate dig into what the ruling actually means, why Malone says it goes far beyond Roundup, and whether an EPA review could flip the whole thing. Trump signs an executive order for regenerative farming, and Iowa turns out to have the highest cancer rate on the planet.

Send us Fan MailFor decades, cancer treatment has rested on three pillars: surgery, chemotherapy, and external beam radiation. A fourth is now taking shape, and it is drawing billions in investment from some of the largest pharmaceutical companies in the world.John Babich, Founder, President, and Chief Scientific Officer of Ratio Therapeutics, joins host David E. Williams to explain how targeted radiotherapeutics pair a tumor-seeking molecule with a radioactive payload, delivering radiation to cancer cells while sparing healthy tissue. He also unpacks what Pluvicto's success in prostate cancer signals for the future of radioligand therapy.

Friday July 3, 2026 Supreme Court Sides with Bayer Over Roundup Litigation

In der heutigen Folge sprechen die Finanzjournalisten Nando Sommerfeldt und Holger Zschäpitz über Bayers Bündelung, das Tesla-Rätsel und 2 sehr volatile E-Auto-Aktien. Außerdem geht es um Deutsche Bank, Vonovia, Aroundtown, LEG Immobilien, Bayer, Samsung Electronics, SK Hynix, Apple, Tesla, Lucid Group, Rivian, UniCredit, Commerzbank, Deutsche Wohnen, SPDR S&P 500 UCITS ETF (WKN: A1JULM), Invesco EQQQ Nasdaq-100 UCITS ETF (WKN: 801498), SPDR Russell 2000 U.S. Small Cap UCITS ETF (WKN: A1XFN1), iShares Edge MSCI USA Momentum Factor UCITS ETF USD (WKN: A2AP36). Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

1% Bonus und eine Beteiligung an Anthropic. Das gibt's grad beim BlackRock Private Equity Fund im Broker von Scalable Capital. Mehr Infos hier. Anthropic will wohl mit Samsung KI-Chip bauen. NVIDIA umwirbt kleine Cloud-Anbieter. OpenAI x US-Regierung? Tesla besser, Aktie fällt trotzdem. Rivian und BYD besser, Aktien steigen. Lucid enttäuscht. Bayer und Vonovia pushen DAX. KNDS-IPO gescheitert. Klimaanlagen boomen, vor allem in den USA. Trane (WKN: A2P09K) baut große Anlagen für Gewerbe und Rechenzentren. Aufträge plus 40%, Service wächst zweistellig. Europa bisher kleines Business, aber vielleicht mit Nachholpotenzial. Beijer Ref (WKN: A3CMPX) macht Klima- und Kältetechnik seit 1866, ist ein Serial Acquirer aus Schweden und hat 700% Rendite in 10 Jahren gemacht. Aber: letzte 5 Jahre seitwärts. Wieviel Rendite ist bei der aktuellen Bewertung drin? Diesen Podcast vom 03.07.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Hinweis: Es gelten Teilnahmebedingungen. Kapitalanlagen bergen Risiken. Es bestehen Liquiditätsbeschränkungen. Bitte beachte die spezifischen Produktinformationen. Teilnahmebedingungen: www.scalable.capital Learn more about your ad choices. Visit megaphone.fm/adchoices

Sermon delivered on the Fifth Sunday After Pentecost, 2026, on a special mission trip to Daleville, Alabama, by Rev. Tobias Bayer.  Epistle: 1 Peter 3, 8-15 | Gospel: Matt. 5, 20-24.

Thanks for coming! Produced by Atlas AG Media Solutions:https://www.atlasmediagroup.usFollow Clayton:https://www.instagram.com/clayton.atlas/Find Neil on Instagram:https://www.instagram.com/neil_denton_farms/Subscribe to @Atlas-Agriculture

In this inspiring interview, Kimberly speaks with Jon Gordon who shares his personal journey through adversity, the power of positive habits, and practical strategies for living a fulfilled, purpose-driven life. Discover how small daily actions like gratitude walks, self-encouragement, and heart coherence can transform your mindset and overall well-being.Chapters00:00 Jon Gordon's Journey to Positivity02:48 The Power of Gratitude and Walking06:07 The Importance of Self-Talk09:02 Navigating Toxic Positivity11:58 Heart Coherence and Emotional Healing15:04 Creating Personal Boundaries17:57 The Role of Prayer in Daily Life21:02 Overcoming Fear and Building Courage23:56 Empowering Others Through Encouragement26:54 The Impact of Love on Fear29:52 Implementing Positive HabitsSponsors: LMNTOFFER: Right now, for my listeners LMNT is offering a free sample pack with any LMNT drink mix purchase at DrinkLMNT.com/FEELGOOD. That's 8 single serving packets FREE with any LMNT any LMNT drink mix purchase. This deal is only available through my link so. Also try the new LMNT Sparkling — a bold, 16-ounce can of sparkling electrolyte water.USE LINK: DrinkLMNT.com/FEELGOODBIRCH BEDS: OFFER: Go to BirchLiving.com/feelgood for 25% off Luxe Mattresses, 30% off Elite Mattresses and 20% off Site wide.USE LINK: BirchLiving.com/feelgoodJon Gordon Resources: Book: THE POWER OF POSITIVE HABITS: Proven Strategies to Exponentially Grow You Website: jongordon.com Social: Instagram: @jongordon11 Facebook: @jongordon X: @JonGordon11 Bio: Jon Gordon's best-selling books and talks have inspired readers and audiences around the world. His principles have been put to the test by numerous Fortune 500 companies, professional and college sports teams, school districts, hospitals, and non-profits. He is the author of 32 books including 18 best sellers and 5 children's books. His books include the timeless classic The Energy Bus which has sold over 3 million copies, The Carpenter which was a top 5 business book of the year, Training Camp, The Power of Positive Leadership, The Power of a Positive Team, The One Truth and his latest release The 7 Commitments of a Great Team. Jon and his tips have been featured on The Today Show, CNN, CNBC, The Golf Channel, Fox and Friends and in numerous magazines and newspapers. His clients include The Los Angeles Dodgers, In-N-Out Burger, The Los Angeles Rams, Campbell Soup, Dell, Publix, Southwest Airlines, The Chicago Bulls, Miami Heat, Truist Bank, Clemson Football, Northwestern Mutual, Bayer, West Point Academy and more. Jon is a graduate of Cornell University and holds a Masters in Teaching from Emory University. He and his training/consulting company are passionate about developing positive leaders, organizations and teams.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

────────────────────────────────────────[00:03:54]Plane Hit Beijing's Tallest Building — It Didn't Collapse, and China Ordered All Footage DeletedPolice told Reuters to leave; bystanders ordered to delete footage; cleaned up within hours; Knight: steel skyscrapers don't collapse in their own footprint.────────────────────────────────────────[00:12:53]Flock Camera Network Builds a Biometric Profile of Your Car — Nationwide Pushback GrowingWSJ reports backlash against license plate surveillance; Knight: tie this to the data center fight — both funded by the same surveillance agenda.────────────────────────────────────────[00:38:17]Federal Blackmail Model: Build the Code, Fund the Governors, Control the StatesTrump gave Republican governors more than entire state budgets during the pandemic; same model now forces green building codes adding $14-20K per home.────────────────────────────────────────[00:39:43]Supreme Court Shields Monsanto From Roundup Cancer Warnings — Trump DOJ Argued Alongside Bayer7-2 ruling says EPA approval preempts state warnings; 65,000 lawsuits pending; Bayer spent $9.1M lobbying in 2025 and placed ex-lobbyists inside EPA and USDA.────────────────────────────────────────[00:49:56]Massey: Government Agencies Protect Corporations From Citizens, Not the ReverseMassey attended Roundup oral arguments; Trump DOJ stood alongside Monsanto; EPA was captured from day one and isn't a constitutional agency.────────────────────────────────────────[01:08:16]Trump Told Evangelical Crowd He'd Be the Greatest Communist — Knight: He Already Checked Every BoxAt Faith and Freedom Coalition, Trump said communists close churches and kill people; he did both in 2020, and the same crowd cheered him both times.────────────────────────────────────────[01:17:46]Trump's Religious Liberty Commission Kicked Off a Pastor for Criticizing Zionism — Knight: It's a Liberty OmissionKerry Baldwin was removed for distinguishing government from religious criticism; you can't freely worship Christ when Israel takes precedence.────────────────────────────────────────[01:38:43]Trump Administration Runs QAnon Memes to Promote Executive Orders — QAnon Is Now FuriousDOD tweeted "Where We Go One We Go Quantum"; QAnon figures say Trump blocked Epstein files, broke every promise, and is cynically co-opting their movement.────────────────────────────────────────[01:50:46]SIDS Falling as Vaccine Skepticism Rises — Washington Post Mocks the Unvaccinated Dating AppUnjected has 65,000 active users in cities with the strictest lockdowns; Knight: people calling them anti-science don't understand science, politics, or human nature.────────────────────────────────────────[01:56:56]Trump Is the Father of the Vaccine — MAGA Defenders Are Inoculating Him From the Accountability He DemandsTrump boasts about Warp Speed; Knight: if you know how bad the vaccine is and still protect him from criticism, you're doing what you accuse the left of doing ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

────────────────────────────────────────[00:03:54]Plane Hit Beijing's Tallest Building — It Didn't Collapse, and China Ordered All Footage DeletedPolice told Reuters to leave; bystanders ordered to delete footage; cleaned up within hours; Knight: steel skyscrapers don't collapse in their own footprint.────────────────────────────────────────[00:12:53]Flock Camera Network Builds a Biometric Profile of Your Car — Nationwide Pushback GrowingWSJ reports backlash against license plate surveillance; Knight: tie this to the data center fight — both funded by the same surveillance agenda.────────────────────────────────────────[00:38:17]Federal Blackmail Model: Build the Code, Fund the Governors, Control the StatesTrump gave Republican governors more than entire state budgets during the pandemic; same model now forces green building codes adding $14-20K per home.────────────────────────────────────────[00:39:43]Supreme Court Shields Monsanto From Roundup Cancer Warnings — Trump DOJ Argued Alongside Bayer7-2 ruling says EPA approval preempts state warnings; 65,000 lawsuits pending; Bayer spent $9.1M lobbying in 2025 and placed ex-lobbyists inside EPA and USDA.────────────────────────────────────────[00:49:56]Massey: Government Agencies Protect Corporations From Citizens, Not the ReverseMassey attended Roundup oral arguments; Trump DOJ stood alongside Monsanto; EPA was captured from day one and isn't a constitutional agency.────────────────────────────────────────[01:08:16]Trump Told Evangelical Crowd He'd Be the Greatest Communist — Knight: He Already Checked Every BoxAt Faith and Freedom Coalition, Trump said communists close churches and kill people; he did both in 2020, and the same crowd cheered him both times.────────────────────────────────────────[01:17:46]Trump's Religious Liberty Commission Kicked Off a Pastor for Criticizing Zionism — Knight: It's a Liberty OmissionKerry Baldwin was removed for distinguishing government from religious criticism; you can't freely worship Christ when Israel takes precedence.────────────────────────────────────────[01:38:43]Trump Administration Runs QAnon Memes to Promote Executive Orders — QAnon Is Now FuriousDOD tweeted "Where We Go One We Go Quantum"; QAnon figures say Trump blocked Epstein files, broke every promise, and is cynically co-opting their movement.────────────────────────────────────────[01:50:46]SIDS Falling as Vaccine Skepticism Rises — Washington Post Mocks the Unvaccinated Dating AppUnjected has 65,000 active users in cities with the strictest lockdowns; Knight: people calling them anti-science don't understand science, politics, or human nature.────────────────────────────────────────[01:56:56]Trump Is the Father of the Vaccine — MAGA Defenders Are Inoculating Him From the Accountability He DemandsTrump boasts about Warp Speed; Knight: if you know how bad the vaccine is and still protect him from criticism, you're doing what you accuse the left of doing ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

TODAY ON THE ROBERT SCOTT BELL SHOW: Live from the Beljanski Integrative Cancer Conference, Supreme Court Bayer Ruling, John Richardson, Laetrile/B17, Canadian Vaccine Injury Program, Embryo DNA Editing, Chris Evert Ovarian Cancer, Disparate Cancer Burden, and MORE! https://robertscottbell.com/live-from-the-beljanski-integrative-cancer-conference-supreme-court-bayer-ruling-john-richardson-canadian-vaccine-injury-program-embryo-dna-editing-chris-evert-ovarian-cancer-again-disparate-can/ Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

How do you get federal herbicide labels? What's the company evolution from his career to Bayer? How Kevin Thoresness impacted the Northern Plains wheat market.

7:00 - Andrea Picotti Bayer on her article "Religious Expression on the rise in public life"7:20 - Clay Rossi discusses the real meaning of seperation of Church and State7:40 - Michelle McAloon offers a perspective on Freedom

The Supreme Court sides with Bayer in a major Roundup ruling that could derail thousands of cancer-warning lawsuits and is drawing sharp criticism from MAHA activists - MAHA activist Vani Hari weighs in. DHS Secretary Markwayne Mullin clashes with House Democrats while detailing the administration's efforts to locate unaccompanied migrant children the federal government lost track of under President Biden. Denmark's center-left government considers a nationwide ban on broadcasting the Islamic call to prayer as it continues pursuing some of Europe's toughest immigration policies. A giraffe named Gracie remains on the loose in the Texas Hill Country as helicopters, drones and local authorities join the search and her owner offers a $5,000 reward.   Cozy Earth: Visit https://www.CozyEarth.com & Use code MEGYN for up to 20% off   Supersure Insurance: Upgrade your business insurance to a year-round SuperAgency at https://Supersure.com/Megyn Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Joe's Premium Subscription: www.standardgrain.comGrain Markets and Other Stuff Links —Apple PodcastsSpotifyTikTokYouTubeFutures and options trading involves risk of loss and is not suitable for everyone.

PODCAST/WEBSITE HEAD: Jamie Dimon succession race narrowsSTANDFIRST: Marianne Lake leaves bank as Doug Petno and Troy Rohrbaugh handed two of its largest divisionsDescription: The race to succeed JPMorgan Chase chief executive Jamie Dimon just got tighter, and the investment chief at insurance group Allianz is warning that the SpaceX bond sale signals markets are in ‘bubble territory'. Plus, the US Supreme Court shielded German pharmaceuticals group Bayer from thousands of lawsuits over its Roundup weedkiller.Mentioned in this podcast:Jamie Dimon promotes two potential successors at JPMorganSpaceX bond sale signals markets are in ‘bubble territory', warns Allianz CIOBayer wins crucial US Supreme Court ruling over Roundup weedkillerTell us your thoughts to enter a prize draw for a chance to win a pair of Bose QuietComfort Headphones worth £229. Take our survey: https://www.feedback.ft.com/c/a/6f9bJBvxsxaEBSIB5esBISOver 18s only. Find full T&Cs here Prize Draw winners' surnames and regions may be made available upon request, as required by the Advertising Standards Authority. If you do not want your information to be made available, please email Privacy.Officer@ft.com upon entry. For more information on your rights and how we use your data, please read our Privacy Policy.Want to get in touch? Email us at podcasts@ft.comNote: The FT does not use generative AI to voice its podcasts The FT News Briefing is produced by Victoria Craig, Sonja Hutson, Saffeya Ahmed, Katya Kumkova, and Fiona Symon. Our editor is Marc Filippino. Our show is mixed by Kelly Garry and Alex Higgins. Additional help from Gavin Kallmann, Michael Lello, Peter Barber and David da Silva. Our intern is Cole van Miltenburg. Our executive producer is Topher Forhecz. Flo Phillips is the FT's global head of audio. The show's theme music is by Metaphor Music.Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

Hohe Opferzahlen nach schweren Erdbeben in Venezuela befürchtet, Wichtiger US-Gerichtserfolg für Bayer im Glyphosat-Prozess, Bund und Länder einigen sich auf Finanzentlastung für Kommunen, In Danzig beraten internationale Geber über den Wiederaufbau der Ukraine, DFB-Team vor WM-Spiel gegen Ecuador, Extreme Hitze in Deutschland ist für viele eine große Herausforderung, Das Wetter